Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]
Discontinued
Reference number: GID-TAG330
Following on from information provided to NICE by the company in November 2011, the appraisal of Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [566] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.